After a rocky few months, Gilead's Trodelvy keeps recent winning streak rolling with priority review

It has been a tumultuous few months for Gilead Sciences’ breast cancer med Trodelvy. But after a surprise comeback at ESMO this year that reignited blockbuster hopes for the franchise, the antibody-drug conjugate is keeping its winning streak rolling.